Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Lithium & Battery Tech ETF (LIT) vs Novavax Inc (NVAX) Price & Performance

Global X Lithium & Battery Tech ETFTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Global X Lithium & Battery Tech ETF vs Novavax Inc — how do they compare? Global X Lithium & Battery Tech ETF trades at $68.91, while Novavax Inc trades at $8.02 (market cap $1.30B). The key difference: Global X Lithium & Battery Tech ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.

LITNVAX
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$91.62$11.19
52-Week Low
$40.80$6.22
Market Cap
$1.30B
Enterprise Value
$800.50M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Lithium & Battery Tech ETF

LIT trades at $66.92, down 2.14% on the day, reflecting recent volatility amid shifting EV market dynamics. The ETF has doubled over the past year, driven by strong momentum in lithium, energy storage, and semiconductor sectors. Key holdings benefit from global EV sales growth, with June marking the fourth consecutive monthly increase. A dividend of $0.32 is scheduled for July 2026, providing income potential.

Outlook remains positive due to structural demand for lithium in EVs and renewables, though risks include Chinese export controls and U.S.-China trade tensions. Analyst sentiment is bullish, citing inflection in lithium markets and reshoring trends. Investors should monitor policy developments and supply chain stability for sustained gains.

Novavax Inc

Novavax (NVAX) trades at $7.86, down 4.26% on the day amid a bearish technical signal, though it has beaten earnings estimates for the last three quarters. The company reported $1.12 billion in revenue for 2025 with a net income of $440.30 million, yet faces negative shareholder equity and cash flow challenges. Recent news highlights stock volatility and shareholder dissent at the AGM, while analyst consensus remains largely bullish with a $14.00 price target.

The outlook for NVAX hinges on sustaining profitability and managing cash burn, with significant upside potential per analyst targets but substantial risks from negative equity, competitive pressures, and reliance on vaccine demand. Investors must weigh the high volatility and financial health concerns against the optimistic Wall Street ratings.

Returns comparison

Trailing returns across standard periods

About Global X Lithium & Battery Tech ETF

LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.

Read more on LIT

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX